All data are based on the daily closing price as of January 22, 2025
s
SK Biopharmaceuticals
326030.KO
75.91 USD
1.16
+1.55%
Overview
Last close
75.91 usd
Market cap
5.94B usd
52 week high
92.25 usd
52 week low
54.55 usd
Target price
86.26 usd
Valuation
P/E
N/A
Forward P/E
81.3008
Price/Sales
18.4389
Price/Book Value
24.9602
Enterprise Value
5.82B usd
EV/Revenue
16.3166
EV/EBITDA
115.1494
Key financials
Revenue TTM
324.46M usd
Gross Profit TTM
295.53M usd
EBITDA TTM
40.15M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
587.58M usd
Net debt
N/A usd
About
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company has collaborative research agreement with Korea Institute of Radiological and Medical Sciences for discovering and developing radiopharmaceutical drug candidates using an alpha-particle emitting radioisotope, actinium-225, for potential cancer treatments. SK Biopharmaceuticals Co., Ltd. was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. operates as a subsidiary of SK Inc.